25 XP   0   0   10

Onconova Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Onconova together

PenkeI guess you are interested in Onconova Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Onconova Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Onconova Therapeutics Inc

I send you an email if I find something interesting about Onconova Therapeutics Inc.

Quick analysis of Onconova (30 sec.)










What can you expect buying and holding a share of Onconova? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.69
Expected worth in 1 year
$-0.21
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-0.90
Return On Investment
-92.5%

For what price can you sell your share?

Current Price per Share
$0.97
Expected price per share
$0.7999 - $1.0699
How sure are you?
50%

1. Valuation of Onconova (5 min.)




Live pricePrice per Share (EOD)

$0.97

Intrinsic Value Per Share

$-1,976.64 - $0.46

Total Value Per Share

$-1,975.95 - $1.15

2. Growth of Onconova (5 min.)




Is Onconova growing?

Current yearPrevious yearGrowGrow %
How rich?$14.5m$40m-$18.9m-89.4%

How much money is Onconova making?

Current yearPrevious yearGrowGrow %
Making money-$4.8m-$4.2m-$610.7k-12.6%
Net Profit Margin-8,591.2%-7,499.8%--

How much money comes from the company's main activities?

3. Financial Health of Onconova (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#643 / 1031

Most Revenue
#659 / 1031

Most Profit
#451 / 1031

Most Efficient
#947 / 1031

What can you expect buying and holding a share of Onconova? (5 min.)

Welcome investor! Onconova's management wants to use your money to grow the business. In return you get a share of Onconova.

What can you expect buying and holding a share of Onconova?

First you should know what it really means to hold a share of Onconova. And how you can make/lose money.

Speculation

The Price per Share of Onconova is $0.97. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Onconova.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Onconova, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.69. Based on the TTM, the Book Value Change Per Share is $-0.22 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Onconova.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.23-23.3%-0.24-24.8%-0.21-21.2%-0.24-25.1%-0.37-38.5%
Usd Book Value Change Per Share-0.21-21.5%-0.22-23.1%-0.19-20.0%0.010.9%-0.09-9.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.21-21.5%-0.22-23.1%-0.19-20.0%0.010.9%-0.09-9.7%
Usd Price Per Share0.71-0.82-1.65-1.64-2.47-
Price to Earnings Ratio-0.79--0.88--2.12--1.93--2.11-
Price-to-Total Gains Ratio-3.41--3.79--9.02--5.85--7.80-
Price to Book Ratio1.03-0.87-0.84-1.11-5.43-
Price-to-Total Gains Ratio-3.41--3.79--9.02--5.85--7.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.97
Number of shares1030
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.220.01
Usd Total Gains Per Share-0.220.01
Gains per Quarter (1030 shares)-231.158.97
Gains per Year (1030 shares)-924.5935.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-925-93503626
20-1849-186007262
30-2774-2785010898
40-3698-37100143134
50-4623-46350179170
60-5548-55600215206
70-6472-64850251242
80-7397-74100287278
90-8321-83350323314
100-9246-92600359350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.046.01.02.1%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.015.01.020.0%9.030.01.022.5%11.033.04.022.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.048.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.015.01.020.0%9.030.01.022.5%11.033.04.022.9%

Fundamentals of Onconova

About Onconova Therapeutics Inc

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Fundamental data was last updated by Penke on 2024-03-21 02:17:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Onconova Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Onconova earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Onconova to the Biotechnology industry mean.
  • A Net Profit Margin of -8,314.0% means that $-83.14 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Onconova Therapeutics Inc:

  • The MRQ is -8,314.0%. The company is making a huge loss. -2
  • The TTM is -8,591.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,314.0%TTM-8,591.2%+277.2%
TTM-8,591.2%YOY-7,499.8%-1,091.4%
TTM-8,591.2%5Y-8,789.0%+197.8%
5Y-8,789.0%10Y-6,575.8%-2,213.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,314.0%-171.8%-8,142.2%
TTM-8,591.2%-205.8%-8,385.4%
YOY-7,499.8%-262.1%-7,237.7%
5Y-8,789.0%-455.6%-8,333.4%
10Y-6,575.8%-589.0%-5,986.8%
1.1.2. Return on Assets

Shows how efficient Onconova is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Onconova to the Biotechnology industry mean.
  • -17.5% Return on Assets means that Onconova generated $-0.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Onconova Therapeutics Inc:

  • The MRQ is -17.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.5%TTM-14.9%-2.6%
TTM-14.9%YOY-8.7%-6.2%
TTM-14.9%5Y-21.2%+6.3%
5Y-21.2%10Y-26.9%+5.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.5%-12.5%-5.0%
TTM-14.9%-12.2%-2.7%
YOY-8.7%-11.2%+2.5%
5Y-21.2%-13.4%-7.8%
10Y-26.9%-14.7%-12.2%
1.1.3. Return on Equity

Shows how efficient Onconova is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Onconova to the Biotechnology industry mean.
  • -32.6% Return on Equity means Onconova generated $-0.33 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Onconova Therapeutics Inc:

  • The MRQ is -32.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -24.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.6%TTM-24.1%-8.5%
TTM-24.1%YOY-10.9%-13.2%
TTM-24.1%5Y-32.9%+8.8%
5Y-32.9%10Y-52.8%+19.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.6%-15.8%-16.8%
TTM-24.1%-15.7%-8.4%
YOY-10.9%-13.9%+3.0%
5Y-32.9%-18.3%-14.6%
10Y-52.8%-19.2%-33.6%

1.2. Operating Efficiency of Onconova Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Onconova is operating .

  • Measures how much profit Onconova makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Onconova to the Biotechnology industry mean.
  • An Operating Margin of -8,928.1% means the company generated $-89.28  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Onconova Therapeutics Inc:

  • The MRQ is -8,928.1%. The company is operating very inefficient. -2
  • The TTM is -9,557.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-8,928.1%TTM-9,557.0%+629.0%
TTM-9,557.0%YOY-7,809.2%-1,747.8%
TTM-9,557.0%5Y-9,176.5%-380.5%
5Y-9,176.5%10Y-6,842.2%-2,334.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,928.1%-299.1%-8,629.0%
TTM-9,557.0%-210.1%-9,346.9%
YOY-7,809.2%-279.7%-7,529.5%
5Y-9,176.5%-459.9%-8,716.6%
10Y-6,842.2%-596.9%-6,245.3%
1.2.2. Operating Ratio

Measures how efficient Onconova is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 90.37 means that the operating costs are $90.37 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Onconova Therapeutics Inc:

  • The MRQ is 90.368. The company is inefficient in keeping operating costs low. -1
  • The TTM is 96.606. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ90.368TTM96.606-6.237
TTM96.606YOY79.070+17.536
TTM96.6065Y92.930+3.676
5Y92.93010Y91.690+1.240
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ90.3682.861+87.507
TTM96.6063.193+93.413
YOY79.0703.615+75.455
5Y92.9305.560+87.370
10Y91.6907.396+84.294

1.3. Liquidity of Onconova Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Onconova is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.79 means the company has $2.79 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Onconova Therapeutics Inc:

  • The MRQ is 2.792. The company is able to pay all its short-term debts. +1
  • The TTM is 3.749. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.792TTM3.749-0.957
TTM3.749YOY7.775-4.027
TTM3.7495Y4.418-0.669
5Y4.41810Y3.871+0.547
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7923.986-1.194
TTM3.7494.440-0.691
YOY7.7755.552+2.223
5Y4.4186.158-1.740
10Y3.8716.492-2.621
1.3.2. Quick Ratio

Measures if Onconova is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Onconova to the Biotechnology industry mean.
  • A Quick Ratio of 2.61 means the company can pay off $2.61 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Onconova Therapeutics Inc:

  • The MRQ is 2.611. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.644. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.611TTM3.644-1.033
TTM3.644YOY7.643-3.999
TTM3.6445Y4.318-0.674
5Y4.31810Y3.950+0.368
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6113.638-1.027
TTM3.6444.168-0.524
YOY7.6435.515+2.128
5Y4.3186.012-1.694
10Y3.9506.209-2.259

1.4. Solvency of Onconova Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Onconova assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Onconova to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.46 means that Onconova assets are financed with 46.3% credit (debt) and the remaining percentage (100% - 46.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Onconova Therapeutics Inc:

  • The MRQ is 0.463. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.368. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.463TTM0.368+0.095
TTM0.368YOY0.196+0.172
TTM0.3685Y0.518-0.150
5Y0.51810Y0.694-0.176
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4630.335+0.128
TTM0.3680.330+0.038
YOY0.1960.267-0.071
5Y0.5180.367+0.151
10Y0.6940.378+0.316
1.4.2. Debt to Equity Ratio

Measures if Onconova is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Onconova to the Biotechnology industry mean.
  • A Debt to Equity ratio of 86.3% means that company has $0.86 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Onconova Therapeutics Inc:

  • The MRQ is 0.863. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.600. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.863TTM0.600+0.263
TTM0.600YOY0.245+0.355
TTM0.6005Y0.728-0.128
5Y0.72810Y1.388-0.660
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8630.376+0.487
TTM0.6000.398+0.202
YOY0.2450.334-0.089
5Y0.7280.429+0.299
10Y1.3880.476+0.912

2. Market Valuation of Onconova Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Onconova generates.

  • Above 15 is considered overpriced but always compare Onconova to the Biotechnology industry mean.
  • A PE ratio of -0.79 means the investor is paying $-0.79 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Onconova Therapeutics Inc:

  • The EOD is -1.075. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.788. Based on the earnings, the company is expensive. -2
  • The TTM is -0.884. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.075MRQ-0.788-0.287
MRQ-0.788TTM-0.884+0.096
TTM-0.884YOY-2.120+1.236
TTM-0.8845Y-1.932+1.048
5Y-1.93210Y-2.111+0.179
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.075-2.643+1.568
MRQ-0.788-2.418+1.630
TTM-0.884-2.742+1.858
YOY-2.120-4.123+2.003
5Y-1.932-6.257+4.325
10Y-2.111-6.478+4.367
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Onconova Therapeutics Inc:

  • The EOD is -1.136. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.833. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.983. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.136MRQ-0.833-0.303
MRQ-0.833TTM-0.983+0.149
TTM-0.983YOY-2.055+1.072
TTM-0.9835Y-1.851+0.869
5Y-1.85110Y-2.054+0.203
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.136-3.244+2.108
MRQ-0.833-2.939+2.106
TTM-0.983-3.478+2.495
YOY-2.055-5.592+3.537
5Y-1.851-8.473+6.622
10Y-2.054-8.881+6.827
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Onconova is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.03 means the investor is paying $1.03 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Onconova Therapeutics Inc:

  • The EOD is 1.403. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.029. Based on the equity, the company is underpriced. +1
  • The TTM is 0.873. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.403MRQ1.029+0.374
MRQ1.029TTM0.873+0.157
TTM0.873YOY0.838+0.035
TTM0.8735Y1.111-0.239
5Y1.11110Y5.426-4.314
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4032.124-0.721
MRQ1.0292.041-1.012
TTM0.8732.118-1.245
YOY0.8382.915-2.077
5Y1.1113.682-2.571
10Y5.4264.114+1.312
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Onconova Therapeutics Inc.

3.1. Institutions holding Onconova Therapeutics Inc

Institutions are holding 7.949% of the shares of Onconova Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc3.3738070861800
2023-12-31BlackRock Inc1.185024888100
2023-12-31Renaissance Technologies Corp0.94670.0002198841151478.2458
2023-12-31Geode Capital Management, LLC0.9182019285800
2023-12-31Two Sigma Advisers, LLC0.37120.000177966-16873-17.7912
2023-12-31State Street Corporation0.251305279000
2023-12-31Two Sigma Investments LLC0.18760.000139395-85308-68.4089
2023-12-31Northern Trust Corp0.146603078300
2023-12-31Beacon Pointe Advisors, LLC0.13570.000328503730.2568
2023-12-31Morgan Stanley - Brokerage Accounts0.0898018855-1255-6.2407
2023-12-31Hillcrest Wealth Advisors - NY, LLC0.07960.00691672300
2023-12-31Millennium Management LLC0.0737015489383532.9072
2023-12-31Mutual Advisors, LLC0.06050.00031270000
2023-12-31UBS Group AG0.036507661759812060.3175
2023-12-31Edmond de Rothschild Holding S.A.0.03170.0001666600
2023-12-31Vermillion & White Wealth Management Group LLC0.02440.0037513351330
2023-12-31Tower Research Capital LLC0.016903549-233-6.1608
2023-12-31Group One Trading, LP0.00770161300
2023-12-31Bank of America Corp0.003206796461957.5758
2023-12-31Royal Bank of Canada0.0019039819192.2705
Total 7.9420.01171668101-71046-4.3%

3.2. Funds holding Onconova Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.741036566100
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.53290.000332197000
2024-01-31Fidelity Extended Market Index0.49950.000210490400
2023-09-30BlackRock Extended Mkt Composite0.23040.00034839900
2023-12-31BlackRock Extended Equity Market K0.2010.000242224-85-0.2009
2024-01-31Fidelity Nasdaq Composite Index0.15810.00023319800
2024-01-31Fidelity Total Market Index0.110302316900
2024-01-31Fidelity Series Total Market Index0.100502110800
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.08010.00021682500
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.068801444100
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.0688014441-351220-96.0507
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.06430.000213513250.1853
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05870.00021232000
2023-12-31Northern Trust Extended Eq Market Idx0.05870.00021232000
2024-02-29Vanguard U.S. Eq Idx £ Acc0.03120654600
2024-01-31Spartan Total Market Index Pool E0.02830594800
2023-12-31SSgA U.S. Extended Market Index Class I0.0260.0002546600
2024-02-29State St US Extended Mkt Indx NL Cl C0.0260.0002546600
2023-12-31Extended Equity Market Fund M0.02490.000252212484.9869
2024-01-31Spartan Extended Market Index Pool E0.02110.0001442900
Total 5.13060.00271077569-351032-32.6%

3.3. Insider Transactions

Insiders are holding 0.779% of the shares of Onconova Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-01-28Abraham N OlerBUY15001.67
2022-01-21Abraham N OlerBUY15002.02
2022-01-14Abraham N OlerBUY15002.2
2022-01-07Abraham N OlerBUY15002.39
2021-11-19Abraham N OlerBUY10003.16
2021-09-28James J MarinoBUY59524.2
2021-09-28Steven M FruchtmanBUY23814.2

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Onconova Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.209-0.224+8%-0.194-7%0.009-2496%-0.094-55%
Book Value Per Share--0.6911.007-31%1.908-64%1.028-33%0.883-22%
Current Ratio--2.7923.749-26%7.775-64%4.418-37%3.871-28%
Debt To Asset Ratio--0.4630.368+26%0.196+136%0.518-11%0.694-33%
Debt To Equity Ratio--0.8630.600+44%0.245+252%0.728+19%1.388-38%
Dividend Per Share----0%-0%-0%-0%
Eps---0.226-0.240+6%-0.206-9%-0.243+8%-0.373+65%
Free Cash Flow Per Share---0.213-0.207-3%-0.198-7%-131.163+61352%-65.776+30717%
Free Cash Flow To Equity Per Share---0.213-0.207-3%-0.199-7%-131.006+61278%-65.608+30638%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.459--------
Intrinsic Value_10Y_min---1976.636--------
Intrinsic Value_1Y_max---0.738--------
Intrinsic Value_1Y_min---253.679--------
Intrinsic Value_3Y_max---1.620--------
Intrinsic Value_3Y_min---718.556--------
Intrinsic Value_5Y_max---1.781--------
Intrinsic Value_5Y_min---1132.036--------
Market Cap20373298.000+27%14941818.76017158727.630-13%34608352.350-57%34367023.284-57%51947446.678-71%
Net Profit Margin---83.140-85.912+3%-74.998-10%-87.890+6%-65.758-21%
Operating Margin---89.281-95.570+7%-78.092-13%-91.765+3%-68.422-23%
Operating Ratio--90.36896.606-6%79.070+14%92.930-3%91.690-1%
Pb Ratio1.403+27%1.0290.873+18%0.838+23%1.111-7%5.426-81%
Pe Ratio-1.075-36%-0.788-0.884+12%-2.120+169%-1.932+145%-2.111+168%
Price Per Share0.970+27%0.7110.817-13%1.648-57%1.636-57%2.473-71%
Price To Free Cash Flow Ratio-1.136-36%-0.833-0.983+18%-2.055+147%-1.851+122%-2.054+147%
Price To Total Gains Ratio-4.650-36%-3.411-3.786+11%-9.024+165%-5.847+71%-7.797+129%
Quick Ratio--2.6113.644-28%7.643-66%4.318-40%3.950-34%
Return On Assets---0.175-0.149-15%-0.087-50%-0.212+21%-0.269+53%
Return On Equity---0.326-0.241-26%-0.109-67%-0.329+1%-0.528+62%
Total Gains Per Share---0.209-0.224+8%-0.194-7%0.009-2496%-0.094-55%
Usd Book Value--14517000.00021150000.000-31%40065500.000-64%21590300.000-33%18555450.000-22%
Usd Book Value Change Per Share---0.209-0.224+8%-0.194-7%0.009-2496%-0.094-55%
Usd Book Value Per Share--0.6911.007-31%1.908-64%1.028-33%0.883-22%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.226-0.240+6%-0.206-9%-0.243+8%-0.373+65%
Usd Free Cash Flow---4483000.000-4350000.000-3%-4168750.000-7%-2754873250.000+61352%-1381518075.000+30717%
Usd Free Cash Flow Per Share---0.213-0.207-3%-0.198-7%-131.163+61352%-65.776+30717%
Usd Free Cash Flow To Equity Per Share---0.213-0.207-3%-0.199-7%-131.006+61278%-65.608+30638%
Usd Market Cap20373298.000+27%14941818.76017158727.630-13%34608352.350-57%34367023.284-57%51947446.678-71%
Usd Price Per Share0.970+27%0.7110.817-13%1.648-57%1.636-57%2.473-71%
Usd Profit---4739000.000-4850500.000+2%-4239750.000-11%-4956100.000+5%-6502000.000+37%
Usd Revenue--57000.00056500.000+1%56500.000+1%154300.000-63%619350.000-91%
Usd Total Gains Per Share---0.209-0.224+8%-0.194-7%0.009-2496%-0.094-55%
 EOD+5 -3MRQTTM+13 -20YOY+3 -305Y+17 -1610Y+16 -17

4.2. Fundamental Score

Let's check the fundamental score of Onconova Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.075
Price to Book Ratio (EOD)Between0-11.403
Net Profit Margin (MRQ)Greater than0-83.140
Operating Margin (MRQ)Greater than0-89.281
Quick Ratio (MRQ)Greater than12.611
Current Ratio (MRQ)Greater than12.792
Debt to Asset Ratio (MRQ)Less than10.463
Debt to Equity Ratio (MRQ)Less than10.863
Return on Equity (MRQ)Greater than0.15-0.326
Return on Assets (MRQ)Greater than0.05-0.175
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Onconova Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5066.488
Ma 20Greater thanMa 500.887
Ma 50Greater thanMa 1000.775
Ma 100Greater thanMa 2000.735
OpenGreater thanClose0.930
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets27,038
Total Liabilities12,521
Total Stockholder Equity14,517
 As reported
Total Liabilities 12,521
Total Stockholder Equity+ 14,517
Total Assets = 27,038

Assets

Total Assets27,038
Total Current Assets27,011
Long-term Assets27
Total Current Assets
Cash And Cash Equivalents 25,244
Net Receivables 18
Inventory 1,446
Other Current Assets 303
Total Current Assets  (as reported)27,011
Total Current Assets  (calculated)27,011
+/-0
Long-term Assets
Property Plant Equipment 26
Long-term Assets Other 1
Long-term Assets  (as reported)27
Long-term Assets  (calculated)27
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,674
Long-term Liabilities2,847
Total Stockholder Equity14,517
Total Current Liabilities
Accounts payable 6,148
Other Current Liabilities 3,300
Total Current Liabilities  (as reported)9,674
Total Current Liabilities  (calculated)9,448
+/- 226
Long-term Liabilities
Long-term Liabilities  (as reported)2,847
Long-term Liabilities  (calculated)0
+/- 2,847
Total Stockholder Equity
Common Stock210
Retained Earnings -478,447
Accumulated Other Comprehensive Income -30
Other Stockholders Equity 492,784
Total Stockholder Equity (as reported)14,517
Total Stockholder Equity (calculated)14,517
+/-0
Other
Capital Stock210
Cash and Short Term Investments 25,244
Common Stock Shares Outstanding 21,003
Current Deferred Revenue226
Liabilities and Stockholders Equity 27,038
Net Debt -25,244
Net Invested Capital 14,517
Net Working Capital 17,337
Property Plant and Equipment Gross 84



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
4,462
0
0
0
83,852
70,759
57,914
122,717
105,153
89,718
74,573
62,274
47,337
36,713
27,737
25,969
23,445
19,642
16,202
28,088
23,233
16,554
16,100
8,802
4,979
8,615
30,203
23,136
17,923
17,923
8,580
6,005
23,674
32,073
28,199
25,207
19,986
48,849
44,378
59,990
55,478
51,422
48,074
43,780
39,372
35,061
30,468
27,038
27,03830,46835,06139,37243,78048,07451,42255,47859,99044,37848,84919,98625,20728,19932,07323,6746,0058,58017,92317,92323,13630,2038,6154,9798,80216,10016,55423,23328,08816,20219,64223,44525,96927,73736,71347,33762,27474,57389,718105,153122,71757,91470,75983,8520004,462
   > Total Current Assets 
0
0
0
0
83,252
69,973
57,048
121,928
104,390
89,024
73,827
61,625
46,905
36,353
27,425
25,684
23,185
19,406
15,990
27,900
23,069
16,413
15,983
8,707
4,903
8,555
30,157
23,104
17,765
17,765
8,429
5,801
23,474
31,876
27,989
25,001
19,784
48,650
44,193
59,936
55,430
51,377
48,033
43,751
39,347
35,039
30,450
27,011
27,01130,45035,03939,34743,75148,03351,37755,43059,93644,19348,65019,78425,00127,98931,87623,4745,8018,42917,76517,76523,10430,1578,5554,9038,70715,98316,41323,06927,90015,99019,40623,18525,68427,42536,35346,90561,62573,82789,024104,390121,92857,04869,97383,2520000
       Cash And Cash Equivalents 
2,713
0
0
0
81,527
67,307
51,181
76,612
60,009
54,624
55,499
42,348
43,582
33,698
25,358
22,197
19,799
16,835
12,818
25,778
21,400
15,389
14,989
7,600
4,024
7,264
29,540
22,384
16,970
16,970
5,882
4,821
22,726
31,036
27,228
24,198
19,025
48,005
43,709
59,378
55,070
50,767
46,533
42,613
38,757
34,220
29,729
25,244
25,24429,72934,22038,75742,61346,53350,76755,07059,37843,70948,00519,02524,19827,22831,03622,7264,8215,88216,97016,97022,38429,5407,2644,0247,60014,98915,38921,40025,77812,81816,83519,79922,19725,35833,69843,58242,34855,49954,62460,00976,61251,18167,30781,5270002,713
       Short-term Investments 
0
0
0
0
0
0
0
39,990
39,994
29,999
14,997
14,999
125
50
50
50
50
50
50
50
50
50
50
50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000505050505050505050505012514,99914,99729,99939,99439,9900000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
132
0
0
1,535
1,504
1,368
2,147
904
31
126
233
57
59
477
72
24
35
35
1,714
23
98
45
41
46
37
38
27
29
28
27
28
28
29
17
17
18
18171729282827282927383746414598231,714353524724775957233126319042,1471,3681,5041,53500132000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
451
0
0
1,838
1,687
0
0
1,121
1,565
794
0
0
743
33
462
593
111
692
33
868
510
573
408
94
542
394
144
158
297
277
31
807
97
734
98
1,446
1,446987349780731277297158144394542944085735108683369211159346233743007941,5651,121001,6871,83800451000000000000
   > Long-term Assets 
0
0
0
0
600
786
866
789
763
694
746
649
432
360
312
285
260
236
212
188
164
141
117
95
76
60
46
32
158
158
151
204
200
197
210
206
202
199
185
54
48
45
41
29
25
22
18
27
27182225294145485418519920220621019720020415115815832466076951171411641882122362602853123604326497466947637898667866000000
       Property Plant Equipment 
507
0
0
0
463
649
729
652
626
557
609
512
420
348
300
273
248
224
200
176
152
129
105
83
64
48
34
20
9
9
1
54
50
47
60
56
52
49
45
42
38
35
31
28
24
21
17
26
26172124283135384245495256604750541992034486483105129152176200224248273300348420512609557626652729649463000507
       Long-term Assets Other 
0
0
0
0
137
137
137
137
137
137
137
137
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
149
149
150
150
150
150
150
150
150
150
140
12
10
10
10
1
1
1
1
1
1111110101012140150150150150150150150150149149121212121212121212121212121212121371371371371371371371370000
> Total Liabilities 
22,884
0
0
0
40,843
42,544
230,856
28,886
24,253
25,354
25,631
26,611
23,715
24,105
23,162
21,771
12,605
12,823
14,155
18,073
18,106
19,265
15,658
14,880
15,840
15,490
14,288
12,276
12,536
12,536
13,126
12,046
12,100
10,725
12,566
12,992
13,811
11,696
11,385
10,324
9,358
9,135
9,590
10,409
11,063
12,185
11,570
12,521
12,52111,57012,18511,06310,4099,5909,1359,35810,32411,38511,69613,81112,99212,56610,72512,10012,04613,12612,53612,53612,27614,28815,49015,84014,88015,65819,26518,10618,07314,15512,82312,60521,77123,16224,10523,71526,61125,63125,35424,25328,886230,85642,54440,84300022,884
   > Total Current Liabilities 
12,081
0
0
0
25,378
28,230
13,307
14,833
10,338
11,556
11,947
13,042
10,259
10,764
9,935
8,657
7,605
7,642
9,095
9,008
10,160
9,883
9,864
8,989
9,976
10,552
9,976
8,207
8,438
8,438
8,746
8,198
8,292
6,910
8,751
9,290
10,021
7,326
7,499
7,025
6,115
5,948
6,460
7,336
8,046
9,224
8,666
9,674
9,6748,6669,2248,0467,3366,4605,9486,1157,0257,4997,32610,0219,2908,7516,9108,2928,1988,7468,4388,4388,2079,97610,5529,9768,9899,8649,88310,1609,0089,0957,6427,6058,6579,93510,76410,25913,04211,94711,55610,33814,83313,30728,23025,37800012,081
       Short-term Debt 
0
0
0
0
3,768
5,149
4,790
7,463
5,436
7,728
6,340
0
5,772
0
0
0
3,723
0
0
4,239
4,184
0
0
0
0
0
0
0
0
4,160
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000004,160000000004,1844,239003,7230005,77206,3407,7285,4367,4634,7905,1493,7680000
       Accounts payable 
5,614
0
0
0
5,517
4,243
4,410
4,405
3,710
3,302
5,027
5,385
4,027
3,857
4,185
3,190
3,421
3,296
2,801
4,071
5,323
5,407
5,681
5,436
6,186
7,034
5,949
4,264
8,212
4,039
4,750
4,524
4,271
4,183
5,148
5,725
4,833
3,988
4,290
4,050
2,757
3,122
3,003
3,760
3,860
4,896
5,071
6,148
6,1485,0714,8963,8603,7603,0033,1222,7574,0504,2903,9884,8335,7255,1484,1834,2714,5244,7504,0398,2124,2645,9497,0346,1865,4365,6815,4075,3234,0712,8013,2963,4213,1904,1853,8574,0275,3855,0273,3023,7104,4054,4104,2435,5170005,614
       Other Current Liabilities 
5,847
0
0
0
12,186
14,852
598
435
404
71
125
7,202
5
6,452
5,295
5,012
6
3,891
5,839
243
198
4,021
3,728
3,098
3,335
3,063
3,572
3,488
226
13
3,770
3,448
3,795
2,501
3,377
3,339
4,962
3,112
2,983
2,749
3,132
2,600
3,231
3,350
3,960
4,102
3,369
3,300
3,3003,3694,1023,9603,3503,2312,6003,1322,7492,9833,1124,9623,3393,3772,5013,7953,4483,770132263,4883,5723,0633,3353,0983,7284,0211982435,8393,89165,0125,2956,45257,2021257140443559814,85212,1860005,847
   > Long-term Liabilities 
0
0
0
0
15,465
14,314
217,549
14,053
13,915
13,798
13,684
13,569
13,456
13,341
13,227
13,114
5,000
5,181
5,060
9,065
7,946
9,382
5,794
5,891
5,864
4,938
4,312
4,069
4,098
4,098
4,380
3,848
3,808
3,815
3,815
3,702
3,790
4,370
3,886
3,299
3,243
3,187
3,130
3,073
3,017
2,961
2,904
2,847
2,8472,9042,9613,0173,0733,1303,1873,2433,2993,8864,3703,7903,7023,8153,8153,8083,8484,3804,0984,0984,0694,3124,9385,8645,8915,7949,3827,9469,0655,0605,1815,00013,11413,22713,34113,45613,56913,68413,79813,91514,053217,54914,31415,4650000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
6
3
2
1
1
0
0
0
0
295
287
4,406
3,401
4,950
1,476
1,686
1,773
4,938
4,312
4,069
4,098
4,468
4,380
3,848
3,808
3,815
3,815
3,702
3,790
4,370
3,886
0
0
0
0
0
0
0
0
0
0000000003,8864,3703,7903,7023,8153,8153,8083,8484,3804,4684,0984,0694,3124,9381,7731,6861,4764,9503,4014,40628729500001123600000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
13,909
13,795
13,682
13,568
13,455
13,341
13,227
13,114
5,000
4,886
4,773
4,659
4,545
4,432
4,318
4,205
4,091
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000004,0914,2054,3184,4324,5454,6594,7734,8865,00013,11413,22713,34113,45513,56813,68213,79513,90900000000
> Total Stockholder Equity
0
0
0
0
43,009
28,215
-172,942
93,831
80,413
63,914
48,519
35,269
22,748
11,758
3,745
3,368
10,010
5,989
1,217
9,185
4,297
-3,541
-388
-6,908
-11,691
-7,705
15,915
10,860
5,387
5,387
-4,546
-6,041
11,574
21,348
15,633
12,215
6,175
37,153
32,993
49,666
46,120
42,287
38,484
33,371
28,309
22,876
18,898
14,517
14,51718,89822,87628,30933,37138,48442,28746,12049,66632,99337,1536,17512,21515,63321,34811,574-6,041-4,5465,3875,38710,86015,915-7,705-11,691-6,908-388-3,5414,2979,1851,2175,98910,0103,3683,74511,75822,74835,26948,51963,91480,41393,831-172,94228,21543,0090000
   Retained Earnings -478,447-473,708-469,458-463,683-458,263-452,865-448,841-444,719-440,955-437,502-433,271-428,556-422,127-415,886-408,491-403,399-397,652-393,057-381,896-381,896-376,245-370,897-367,406-362,316-356,109-349,149-346,565-338,224-332,777-331,178-325,797-318,557-321,749-315,876-306,921-294,578-281,206-266,328-249,575-230,896-216,281-195,760-183,198-168,3530000
   Accumulated Other Comprehensive Income 
0
0
0
0
-1,348
7
5
-18
1
-1,914
-2,012
-8
-13
-43
-14
-18
-22
-16
-19
-17
-31
-26
-10
-1
3
11
-5
-7
-2,219
-12
-14
-27
-18
-24
-17
-2
14
-2
2
-6
-14
-21
-41
-61
-33
-27
-28
-30
-30-28-27-33-61-41-21-14-62-214-2-17-24-18-27-14-12-2,219-7-5113-1-10-26-31-17-19-16-22-18-14-43-13-8-2,012-1,9141-1857-1,3480000
   Capital Surplus 
0
0
0
0
0
0
0
0
311,093
313,272
314,630
316,266
317,122
318,505
319,418
324,898
328,334
331,528
332,387
341,911
342,484
342,982
348,672
349,103
350,514
359,496
385,966
387,055
387,238
387,919
388,465
391,556
413,879
428,189
429,794
432,499
432,858
468,059
470,335
0
0
0
0
0
0
0
0
0
000000000470,335468,059432,858432,499429,794428,189413,879391,556388,465387,919387,238387,055385,966359,496350,514349,103348,672342,982342,484341,911332,387331,528328,334324,898319,418318,505317,122316,266314,630313,272311,09300000000
   Treasury Stock000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue226
Cost of Revenue--
Gross Profit-226
 
Operating Income (+$)
Gross Profit-
Operating Expense-21,796
Operating Income-21,570-21,796
 
Operating Expense (+$)
Research Development12,769
Selling General Administrative9,027
Selling And Marketing Expenses-
Operating Expense21,79621,796
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-0
Net Interest Income-
 
Pretax Income (+$)
Operating Income-21,570
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-20,184-22,956
EBIT - interestExpense = 0
-20,184
-20,184
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--20,184
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-20,184
Tax Provision--
Net Income From Continuing Ops-20,184-20,184
Net Income-20,184
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net1,3860
 

Technical Analysis of Onconova
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Onconova. The general trend of Onconova is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Onconova's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Onconova Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.961 < 1.05 < 1.0699.

The bearish price targets are: 0.8241 > 0.8099 > 0.7999.

Tweet this
Onconova Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Onconova Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Onconova Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Onconova Therapeutics Inc. The current macd is 0.03419694.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Onconova price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Onconova. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Onconova price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Onconova Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartOnconova Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Onconova Therapeutics Inc. The current adx is 43.93.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Onconova shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Onconova Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Onconova Therapeutics Inc. The current sar is 1.01628737.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Onconova Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Onconova Therapeutics Inc. The current rsi is 66.49. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Onconova Therapeutics Inc Daily Relative Strength Index (RSI) ChartOnconova Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Onconova Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Onconova price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Onconova Therapeutics Inc Daily Stochastic Oscillator ChartOnconova Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Onconova Therapeutics Inc. The current cci is 121.11.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Onconova Therapeutics Inc Daily Commodity Channel Index (CCI) ChartOnconova Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Onconova Therapeutics Inc. The current cmo is 40.44.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Onconova Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartOnconova Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Onconova Therapeutics Inc. The current willr is -35.41389996.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Onconova is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Onconova Therapeutics Inc Daily Williams %R ChartOnconova Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Onconova Therapeutics Inc.

Onconova Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Onconova Therapeutics Inc. The current atr is 0.06331413.

Onconova Therapeutics Inc Daily Average True Range (ATR) ChartOnconova Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Onconova Therapeutics Inc. The current obv is 37,955,493.

Onconova Therapeutics Inc Daily On-Balance Volume (OBV) ChartOnconova Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Onconova Therapeutics Inc. The current mfi is 63.29.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Onconova Therapeutics Inc Daily Money Flow Index (MFI) ChartOnconova Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Onconova Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Onconova Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Onconova Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5066.488
Ma 20Greater thanMa 500.887
Ma 50Greater thanMa 1000.775
Ma 100Greater thanMa 2000.735
OpenGreater thanClose0.930
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Onconova with someone you think should read this too:
  • Are you bullish or bearish on Onconova? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Onconova? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Onconova Therapeutics Inc

I send you an email if I find something interesting about Onconova Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Onconova Therapeutics Inc.

Receive notifications about Onconova Therapeutics Inc in your mailbox!